The role of EZH2 in tumour progression

被引：279

作者：

Chang, C-J ^{[1
]}

Hung, M-C ^{[1
,2
,3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA

[2] China Med Univ & Hosp, Ctr Mol Med, Taichung 404, Taiwan

[3] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung 404, Taiwan

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 106卷 / 02期

关键词：

EZH2; Polycomb proteins; histone methyltransferase; POLYCOMB GROUP PROTEINS; PROSTATE-CANCER; STEM-CELLS; SUPPRESSES METHYLATION; MEDIATED REPRESSION; PHOSPHORYLATION; DIFFERENTIATION; OVEREXPRESSION; TRANSFORMATION; METASTASIS;

D O I：

10.1038/bjc.2011.551

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence. British Journal of Cancer (2012) 106, 243-247. doi:10.1038/bjc.2011.551 www.bjcancer.com Published online 20 December 2011 (C) 2012 Cancer Research UK

引用

页码：243 / 247

页数：5

共 34 条

[1] EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies [J].

Abdel-Wahab, Omar ;

Levine, Ross L. .

CANCER CELL, 2010, 18 (02) :105-107

[2] The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation [J].

Boukarabila, Hanane ;

Saurin, Andrew J. ;

Batsche, Eric ;

Mossadegh, Noushine ;

van Lohuizen, Maarten ;

Otte, Arie P. ;

Pradel, Jacques ;

Muchardt, Christian ;

Sieweke, Michael ;

Duprez, Estelle .

GENES & DEVELOPMENT, 2009, 23 (10) :1195-1206

[3] EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].

Adrian P. Bracken ;

Diego Pasini ;

Maria Capra ;

Elena Prosperini ;

Elena Colli ;

Kristian Helin .

The EMBO Journal, 2003, 22 (20) :5323-5335

[4] Repression of E-cadherin by the polycomb group protein EZH2 in cancer [J].

Cao, Q. ;

Yu, J. ;

Dhanasekaran, S. M. ;

Kim, J. H. ;

Mani, R-S ;

Tomlins, S. A. ;

Mehra, R. ;

Laxman, B. ;

Cao, X. ;

Yu, J. ;

Kleer, C. G. ;

Varambally, S. ;

Chinnaiyan, A. M. .

ONCOGENE, 2008, 27 (58) :7274-7284

[5] Akt-mediated phsophorylationof EZH2 suppresses methylation of lysine 27 in histone H3 [J].

Cha, TL ;

Zhou, BHP ;

Xia, WY ;

Wu, YD ;

Yang, CC ;

Chen, CT ;

Ping, B ;

Otte, AP ;

Hung, MC .

SCIENCE, 2005, 310 (5746) :306-310

[6] EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling [J].

Chang, Chun-Ju ;

Yang, Jer-Yen ;

Xia, Weiya ;

Chen, Chun-Te ;

Xie, Xiaoming ;

Chao, Chi-Hong ;

Woodward, Wendy A. ;

Hsu, Jung-Mao ;

Hortobagyi, Gabriel N. ;

Hung, Mien-Chie .

CANCER CELL, 2011, 19 (01) :86-100

[7] Aberrations of EZH2 in Cancer [J].

Chase, Andrew ;

Cross, Nicholas C. P. .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2613-2618

[8] Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2 [J].

Chen, Shuai ;

Bohrer, Laura R. ;

Rai, Aswathy N. ;

Pan, Yunqian ;

Gan, Lu ;

Zhou, Xianzheng ;

Bagchi, Anindya ;

Simon, Jeffrey A. ;

Huang, Haojie .

NATURE CELL BIOLOGY, 2010, 12 (11) :1108-U118

[9] Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer [J].

Crea, Francesco ;

Hurt, Elaine M. ;

Mathews, Lesley A. ;

Cabarcas, Stephanie M. ;

Sun, Lei ;

Marquez, Victor E. ;

Danesi, Romano ;

Farrar, William L. .

MOLECULAR CANCER, 2011, 10

[10] Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1 [J].

Gonzalez, M. E. ;

Li, X. ;

Toy, K. ;

DuPrie, M. ;

Ventura, A. C. ;

Banerjee, M. ;

Ljungman, M. ;

Merajver, S. D. ;

Kleer, C. G. .

ONCOGENE, 2009, 28 (06) :843-853

← 1 2 3 4 →